Amphastar Pharmaceuticals Inc

AMPH is in a Stage 1 early consolidation after a terminal decline, trading in a tight range around its short EMAs and 50 DMA. Mean-reversion eligibility and strong free-cash-flow metrics support a tactical bounce from the well-defended demand zone, consistent with the Free Cash Flow + Buybacks strategy’s emphasis on high-quality entry points. However, indicators and volume remain neutral with no clear timing edge. Execution should be patient for pullback-based entries near support.

• ↑Proprietary products to drive revenue: pipeline share from 37% to 85% by 2026
• ↑Reported Q2 net revenue of $183.9M (+5% YoY), surpassing $179.7M estimate
• ↓BAQSIMI® down 3% and Primatene MIST® down 8% signal revenue headwinds